Project Oncology®

What are some of the most recent advancements in RET diagnostics? Dr. Balazs Halmos discusses molecular testing for patients with non-small cell lung cancer, or NSCLC, and best practices to use when treating patients with RET alterations.

Often diagnosed in its later stages, lung cancer often leaves little time for treatment. But an preventive screening technique may help detect this disease early on. Andrea Mckee discusses the lung cancer screening guidelines from the U.S. Preventative Services Task Force and what to know about prevention screening using a low dose computed tomography (LDCT) to help close the time gap.

Does immunotherapy play a role in improving quality of life and survival for patients with ovarian cancer? Learn how experts are determining immunotherapy’s place in the treatment plan during the PARP era and what’s on the horizon.

Are dMMR and MSI-H both markers that will soon replace or work in conjunction with PD-L1 when determining immunotherapy for patients with metastatic NSCLC? Accurate testing and treatment selection is critical in identifying patients who will benefit from these therapies. Dr. Federico Cappuzzo, Dr. Solange Peters, and Professor Yi-Long Wu discuss emerging data from the recent WCLC, ESMO, and ASCO virtual conferences and offer their international and regional perspectives on the evolving use of immunotherapies in advanced NSCLC.

Although outcomes have improved for women with HER2-positive early-stage breast cancer, patients who do not have a pathologic complete response after neoadjuvant therapy are at an increased risk for recurrence and need further improvements in therapy options.

In this activity, Drs. Charles Geyer and Hope Rugo discuss how the management of HER2-positive early-stage breast cancer has evolved, the continued quest to reduce the burden of therapy on patients—and how subcutaneous approaches are achieving this—and other challenges in the treatment continuum.

Our understanding of the biology of triple-negative breast cancer (TNBC) is leading to the development of more targeted therapies. Dr. Peter Schmid and Dr. Javier Cortés discuss the role of immunotherapies in the treatment of metastatic TNBC and how to determine if your patient is eligible for combination immunotherapies.

What are the current rationales for the use of adjuvant therapies in the management of early-stage breast cancer patients? Here to share some insights is Dr. Lajos Pusztai, Director of Breast Cancer Translational Research at the Yale Cancer Center.

There’s been a sharp decrease in breast cancer diagnoses since the beginning of the COVID-19 pandemic. But that doesn’t necessarily mean there are any fewer cases out there. Here to share how the COVID-19 pandemic has impacted breast cancer screening and how we can increase access to this essential proactive measure is Dr. Randy Miles, Clinical Service Chief in the Division of Breast Imaging at the Department of Radiology at the Massachusetts General Hospital.

What are the current rationales for the use of adjuvant therapies in the management of early-stage breast cancer patients? Here to share some insights is Dr. Lajos Pusztai, Director of Breast Cancer Translational Research at the Yale Cancer Center.

There’s been a sharp decrease in breast cancer diagnoses since the beginning of the COVID-19 pandemic. But that doesn’t necessarily mean there are any fewer cases out there. Here to share how the COVID-19 pandemic has impacted breast cancer screening and how we can increase access to this essential proactive measure is Dr. Randy Miles, Clinical Service Chief in the Division of Breast Imaging at the Department of Radiology at the Massachusetts General Hospital.